Panavance Therapeutics Inc. (“Panavance” or the “Company”) today announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Tuesday, November 8, 2022 at 12:00 PM ET at BioFuture 2022 being held in New York, NY.
BERWYN, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancer’s energy metabolism and improve quality of life for patients, today announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Tuesday, November 8, 2022 at 12:00 PM ET at BioFuture 2022 being held in New York, NY.
Mr. Bosch will provide a Company overview and discuss its lead program, GP-2250, a tumor cell selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer cell death. GP-2250 is currently in a Phase 1 clinical trial with plans to initiate registration directed trials in both pancreatic and ovarian cancers in late 2023.
The presentation will be available to those registered to attend the in-person conference. In addition to the presentation, members of the executive leadership team will be available for in person meetings. To schedule a meeting, please request through the conference’s partnering platform. For more information, please visit the conference website here.
About Panavance Therapeutics
Panavance Therapeutics Inc. is a privately-held, clinical-stage pharmaceutical company developing a novel oncology platform focused on improving the effectiveness of cancer treatments and quality of life for patients. The Company, located in Berwyn, PA was founded in 2021 and continues to be funded by Avensis Pharma AG, a subsidiary of Swiss privately held Ed. Geistlich Söhne AG für Chemische Industrie. Panavance’s lead program, GP-2250, is a tumor cell selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer cell death. GP-2250 is currently in a Phase 1 trial in pancreatic cancer patients. The Company is rapidly advancing towards a pivotal Phase 3 clinical trial, projected to start in the second half of 2023, as a first-line maintenance therapy for pancreatic cancer in non-BRCA mutation patients, a population for which there are no FDA approved agents. Additionally, GP-2250 is being developed for the treatment of ovarian cancer in combination with leading anti-cancer agents based on promising preclinical data. The Company expects to initiate a potential registration directed Phase 1/2 clinical study in ovarian cancer which is expected to start in the second half of 2023. GP-2250 has broad oncology applications and has the potential to be effective in additional indications, including melanoma, squamous cell, breast and colorectal cancers.
For more information, please visit panavance.com and connect with the Company on Twitter and LinkedIn.
References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Panavance is not responsible for the contents of third-party websites.
Forward Looking Statements
This press release contains “forward-looking statements” that are based on Panavance’s current expectations and subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation, Panavance’s ability to execute its business plan and fund its ongoing business activities as planned, Panavance’s ability to develop and commercialize its product candidates, Panavance’s expectations related to results of clinical trials and studies, and Panavance’s ability to obtain FDA approval of GP-2250. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this press release are made as of this date, and Panavance undertakes no duty to update such information except as required under applicable law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
panavance@jtcir.com
